Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917951 | 0.71 | TP53 (0.39) | TP53LMNAALDH1A1TSHRTHRB | |
| SCHEMBL31415558 | 0.71 | TP53 (0.39) | TP53LMNAALDH1A1TSHRTHRB | |
| SCHEMBL7266017 | 0.69 | GRIK1 (0.31) | — | |
| SCHEMBL31177890 | 0.69 | — | — | |
| SCHEMBL451424 | 0.69 | — | — | |
| SCHEMBL222605 | 0.69 | LMNA (0.35) | LMNAALDH1A1TDP1ALOX15 | |
| SCHEMBL5141995 | 0.69 | — | — | |
| SCHEMBL15067177 | 0.67 | — | — | |
| SCHEMBL15921098 | 0.67 | TP53 (0.42) | TP53GABRR1LMNAALDH1A1TSHR | |
| SCHEMBL7205478 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109437-B1 | COSMETIC COMPOSITION CONTAINING NOVEL FRACTAL PARTICLE BASED GELS HAVING IMPROVED OPTICAL PROPERTIES | AVON PROD INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-8603505-B2 | Cosmetic composition containing novel fractal particle based gels having improved optical properties | AVON PRODUCTS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20080152680-A1 | Cosmetic composition containing novel fractal particle based gels having improved optical properties | CITIBANK, N.A., LONDON BRANCH | 2008-06-26 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| EP-1023299-B1 | COMBINED GENERATION OF PHOSPHINIC ACID DERIVATIVES | AVENTIS CROPSCIENCE GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-1023299-A1 | COMBINED GENERATION OF PHOSPHINIC ACID DERIVATIVES | Aventis CropScience GmbH (DE) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999019332-A1 | COMBINED GENERATION OF PHOSPHINIC ACID DERIVATIVES | AVENTIS CROPSCIENCE GMBH (DE) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TP53 3414/4885GABRR1 4587/4885LMNA 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.